Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Risk Factors for Rheumatoid Arthritis

Advertisements

Figure 1 Lymphocytes during the disease

Risk Factors for Rheumatoid Arthritis

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

of different experimental arthritis models

Figure 3 Example of how a noncoding regulatory rheumatoid

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Grip strength across the lifecourse

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Enthesitis versus synovitis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Simplified T cell and antigen presenting

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 1 Location of HLA variants known to be associated

Figure 3 Defects in the T cell receptor signalling pathway

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 1 Pharmacodynamics of methotrexate in RA

Figure 3 Hypothetical mechanisms of smoking-associated

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Overlap of associated loci among five rheumatic diseases

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The current model of the pathogenesis of SLE

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Figure 6 Metabolism of pterins

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Nat. Rev. Cardiol. doi: /nrcardio

Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Nat. Rev. Rheumatol. doi: /nrrheum

EULAR-defined characteristics describing arthralgia at risk for RA

Figure 1 The role of macrophages in RA

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically suspect arthralgia divided in four.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Satisfaction with control of RA

Nat. Rev. Rheumatol. doi: /nrrheum

Joint pain location and severity.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.185 Figure 2 Different approaches for identifying individuals at risk of developing rheumatoid arthritis Figure 2 | Different approaches for identifying individuals at risk of developing rheumatoid arthritis. This figure presents the different phases of rheumatoid arthritis (RA) development proposed by the EULAR study group13, in relation to the possible types of prevention (primary, secondary or tertiary). In addition, it illustrates the risk of RA development for different groups of individuals identified in different settings, and the relative sizes of these groups. Not all patients will pass through every phase of RA development and some phases can be present at the same time (for example, smoking, autoimmunity and arthralgia). FDR, first-degree relative; CSA, clinically suspect arthralgia; MSK, musculoskeletal; UA, undifferentiated arthritis. van Steenbergen, H. W. et al. (2017) Preventing progression from arthralgia to arthritis: targeting the right patients Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.185